Strides Pharma Science Ltd
Strides Pharma Science Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Strides Pharma aims to achieve around $400 million revenue from the US market by FY'28, with growth expected over the next 9 quarters. The company aims to reach US revenues of $400 million by FY'28 with consistent growth expected over the next 2 years. - Operational PAT grew 65% in the 9-month period with an operational EPS of Rs.
From Strides Pharma Science Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Strides Pharma aims to achieve around $400 million revenue from the US market by FY'28, with growth expected over the next 9 quarters.
- Ex-US markets (other regulated and growth markets) are growing faster than anticipated, now contributing 47% of Q3 FY'26 revenues with 20% YoY growth; the gap between US and Ex-US revenues has significantly narrowed.
- Growth drivers include ramping up dormant products, control substances normalizing, investing in complex generics like nasal sprays and 505(b)(2) programs, and expanding product portfolios within existing geographies.
- The company foresees consistent growth rather than quarter-to-quarter spikes, with multiple levers in place across markets.
- Planned launches and portfolio expansions will sustain growth; the focus remains on profitability and EBITDA margin expansion.
2 more points from Strides Pharma Science Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Strides Pharma Science Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Maintenance CAPEX is on track in the range of Rs. 100 crore to Rs. 125 crore.
- Rs. 284 crores invested in CAPEX for tangible and intangible assets during the 9-month period.
- Investments are aimed at driving growth in both the US and Ex-US markets.
2 more points from Strides Pharma Science Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Strides Pharma Science Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Order book in access market currently subdued due to reduced donor funding, especially from large institutions like the Global Fund.
- Several countries have lowered their contributions, causing a significant reduction in orders not only for Strides but industry-wide.
- Allocation periods are rolling over as donors have not fulfilled obligations.
- Some countries are increasing contributions to fill funding gaps caused by others, but the gap remains large.
2 more points from Strides Pharma Science Ltd's call on order book
Create a free account to keep reading this call
Strides Pharma Science Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.4K Cr, net profit ₹134 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Strides Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Guj. Themis Bio. (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Strides Pharma Science Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Strides Pharma Science Ltd Q3 FY26 results?
Strides Pharma aims to achieve around $400 million revenue from the US market by FY'28, with growth expected over the next 9 quarters. The company aims to reach US revenues of $400 million by FY'28 with consistent growth expected over the next 2 years. - Operational PAT grew 65% in the 9-month period with an operational EPS of Rs.
What is Strides Pharma Science Ltd share price analysis?
Strides Pharma Science Ltd currently shows a neutral. The stock trades at a P/E of 15.4 with a market cap of ₹8,944 Cr. Investors should review the full earnings analysis for detailed insights.
Is Strides Pharma Science Ltd planning capital expenditure?
Maintenance CAPEX is on track in the range of Rs.
Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.